title: Multiple Myeloma Market Will Expand With Launch of Monoclonal Antibodies.
abstract: Analysts foresee substantial growth in the multiple myeloma market in the next decade, driven mainly by the monoclonal antibodies elotuzumab and daratumumab.
authors.forename: Chris
authors.initials: C
authors.lastname: Fellner